MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/640/0.01/21.03.25 | Market Closed - Börse Stuttgart 15:00:31 2024-05-31 EDT | ||
| 0.109 EUR | +3.81% |
|
| Current month | +32.91% | ||
| 1 month | +32.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.109 | +3.81% |
| 24-05-30 | 0.105 | -0.94% |
| 24-05-29 | 0.106 | -11.67% |
| 24-05-28 | 0.12 | +4.35% |
| 24-05-27 | 0.115 | +3.60% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 03:00 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG29NK |
| ISIN | DE000MG29NK8 |
| Date issued | 2024-04-12 |
| Strike | 640 $ |
| Maturity | 2025-03-21 (294 Days) |
| Parity | 100 : 1 |
| Emission price | 0.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.12 € |
|---|---|
| Lowest since issue | 0.073 € |
| Spread | 0.01 € |
| Spread % | 8.06% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
443
USD
Average target price
463.5
USD
Spread / Average Target
+4.62%
- Stock Market
- Warrants
- Warrant
